Pharmadax is a leading drug development and generic specialty pharma company that is dedicated to improving the quality of life for patients worldwide. With a commitment to professionalism, honesty, and decisiveness, Pharmadax uses its unique formulation technology platform to develop modified release oral solid formulations. The company focuses on various therapeutic segments, specializing in CNS (Central Nervous System) and CVS (Cardiovascular System) areas.

Pharmadax offers a range of business offerings, including co-developing and marketing partnerships, dossier development and technology transfer, and regulated market opportunities for tablets in CMO (Contract Manufacturing Organization). With a highly skilled and experienced team, Pharmadax ensures the efficient filing of dossiers and the development of bioequivalent products. Their core technology of high precision modified release allows for flexibility in bringing innovative pharmaceutical products to market.

Pharmadax's dedication to quality and compliance extends to their products, people, and partnerships. With a global presence in five countries, including Taiwan, China, and India, Pharmadax is always available to discuss and meet the requirements of their customers